Saturday, 31 October 2026European Markets

CBO TERRITORIA And SELVAAG BOLIG Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - cbo territoria (cbot.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
cbo territoria (cbot.pa) €3.71 6.37% 5.88%
selvaag bolig (sbo.ol) kr37.30 5.32% 9.85%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. cbo territoria (cbot.pa)

6.37% forward dividend yield and 5.88% return on equity

cbo territoria sa engages in the urban planning and development, and property development and investment activities in france. the company develops and sells housings, retail parks, offices, industrial premises, shops, plots of land, business premises, and warehouses. it is also involved in the leisure, catering, marketing, and coworking businesses. cbo territoria sa was incorporated in 2004 and is headquartered in sainte-marie, france.

earnings per share

as for profitability, cbo territoria has a trailing twelve months eps of €0.43.

pe ratio

cbo territoria has a trailing twelve months price to earnings ratio of 8.63. meaning, the purchaser of the share is investing €8.63 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.88%.

revenue growth

year-on-year quarterly revenue growth declined by 11.6%, now sitting on 85.09m for the twelve trailing months.

volume

today's last reported volume for cbo territoria is 13595 which is 7.14% above its average volume of 12688.

yearly top and bottom value

cbo territoria's stock is valued at €3.71 at 22:30 est, under its 52-week high of €3.93 and above its 52-week low of €3.48.

dividend yield

as stated by morningstar, inc., the next dividend payment is on jun 12, 2024, the estimated forward annual dividend rate is 0.24 and the estimated forward annual dividend yield is 6.37%.

more news about cbo territoria.

2. selvaag bolig (sbo.ol)

5.32% forward dividend yield and 9.85% return on equity

selvaag bolig asa, a housing development company, engages in the development, construction, and sale of residential properties primarily in greater oslo, bergen, stavanger, trondheim, and stockholm. it operates through property development and other segments. the company also offers project management services. selvaag bolig asa was incorporated in 2008 and is headquartered in oslo, norway. selvaag bolig asa operates as a subsidiary of selvaag as.

earnings per share

as for profitability, selvaag bolig has a trailing twelve months eps of kr2.52.

pe ratio

selvaag bolig has a trailing twelve months price to earnings ratio of 14.8. meaning, the purchaser of the share is investing kr14.8 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 9.85%.

volatility

selvaag bolig's last week, last month's, and last quarter's current intraday variation average was a negative 0.27%, a positive 0.32%, and a positive 1.67%.

selvaag bolig's highest amplitude of average volatility was 0.94% (last week), 1.64% (last month), and 1.67% (last quarter).

more news about selvaag bolig.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com